次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

ドラッグデリバリー技術の世界市場2014-2024年

Drug Delivery Technologies Market Forecast 2014-2024

出版元:Visiongain(英国)出版元情報LinkIcon
発行年:2014年4月
定価 Single User License(1名様ライセンス) 1,799 GBP(英国ポンド) / Department License(5名様ライセンス) 2,999GBP/ Site License 4,999GBP / Global Site License 6,999GBP
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email
当調査レポートは英文272ページになります。
商品コード:VGN214

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
Visiongain社では、ドラッグデリバリー技術の世界市場は2014年に1381億ドルに達し、2024年にかけて堅調な成長が続くと予測しています。当レポートでは同市場の2024年に至る市場予測、詳細なセグメント別予測分析に加え、市場動向、リーディング企業情報などを概略以下の構成でお届けしています。

【レポート構成概要】
・ドラッグデリバリー技術の世界市場予測2014-2024年
・全202ページ、157個のデータ表、グラフ類で分析定量化
・業界専門家オピニオンインタビュー:
• Dr. Sven Frokjaer, Dean and Professor of Pharmaceutical Sciences, University of Copenhagen, Denmark
• Dr. Claus Michael Lehr, Head of Department, Drug Delivery at Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)

・セグメント別市場予測2014-2024年
• 経鼻Nasal drug delivery technologies market
• 眼内Ocular drug delivery technologies market
• 経皮Transdermal drug delivery technologies market
• 注射/インプラントInjectable/implants drug delivery technologies market
• 吸入Inhalation drug delivery technologies market
• 経口Oral drug delivery technologies market

・製薬分野別・市場予測2014-2024年
• 組換え凝固因子Recombinant coagulation factors
• インスリンInsulins
• モノクローナル抗体Monoclonal antibodies
• 果粒球コロニー刺激因子G-CSF agents
• エリスロポエチンErythropoietins
• インターフェロン Interferons
• バイオシミラーと関連薬剤Biosimilars and related agents
• ワクチンVaccines
• その他の治療用タンパク質Other therapeutic proteins

主要国別市場予測2014-2024年
• 米国VGN214_Drug Delivery Technologies Market Forecast 2014-2024 Cover.jpgレポート表紙
• 日本
• ドイツ
• フランス
• 英国
• イタリア
• スペイン
• ブラジル
• ロシア
• インド
• 中国
• メキシコ
• 韓国
• その他Rest of the World

・リーディング企業18社プロフィール。会社情報、市場における歴史、直近業績、主要製品情報、新製品、提携、M&A等
• 3M
• Aradigm Corporation
• Vectura Group
• Applied Pharma Research
• Catalent Pharma Solutions
• Emisphere Technologies
• Ethypharm
• Glycologic
• Alkermes
• Antares Pharma
• Bioject Medical Technologies
• Pacira Pharmaceuticals
• Nanopass Technologies
• Noven Pharmaceuticals
• CIMA Labs
• Columbia Laboratories
• Generex Biotechnology Corporation
• pSivida

・市場動向分析(諸論点)
• コスト削減と効率化
• 製品ライフサイクル管理ツールとしてのドラッグデリバリー技術
• 製品独占権の保持
• 薬剤の治療価値の最適化
• 安全性と患者(服薬)コンプライアンス
• 製品差別化とカスタマイズ
• 薬代償還と立法規制

【レポート詳細目次は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

Drug Delivery Technologies Market Forecast 2014-2024

Table of Contents

1. Report Overview

1.1 Global Drug Delivery Technologies Market Overview
1.2 Global Drug Delivery Technologies Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. An Introduction to Drug Delivery

2.1 Drug Delivery Technologies (DDT)
2.2 Drug Delivery Technologies - Types
2.2.1 Injection As a Route of Drug Delivery
2.2.2 Needle-free Transdermal Delivery
2.2.3 Oral Delivery Technologies
2.2.4 Inhalation or Spray
2.3 Sustained/Controlled Release Systems
2.4 Biopharmaceuticals
2.4.1 An introduction to the Biologic Drugs Market
2.4.2 Biologics: A Rising Drugs Market
2.4.3 Biotech Drugs with Associated Drug Delivery Technologies
2.4.4 Pegylated Interferons
2.4.5 Stiff Competition in Insulin Market Stimulating Investment in Drug Delivery Technologies
2.4.6 The Main Challenges Facing Biological Drug Delivery
2.5 Market Definition

3. The Global Drug Delivery Technologies Market, 2014-2024

3.1 Global Drug Delivery Technologies: Market Overview
3.1.1 Drug Delivery Technologies: A Growing Market
3.2 The Global Drug Delivery Technologies Market in 2013
3.2.1 Global Drug Delivery Technologies: Market Forecast 2014-2024
3.2.2 Changing Market Shares by Sector 2014-2024
3.3 Oral Drug Delivery Technologies Market 2014-2024
3.3.1 Oral Drug Delivery Technologies: Market Forecast 2014-2024
3.4 Inhalation Drug Delivery Technologies Market 2014-2024
3.4.1 Inhalation Drug Delivery Technologies: Market Forecast 2014-2024
3.5 Injectable/Implants Drug Delivery Technologies Market 2014-2024
3.5.1 Injectable/Implants Drug Delivery Technologies: Market Forecast 2014-2024
3.6 Transdermal Drug Delivery Technologies Market 2014-2024
3.6.1 Transdermal Drug Delivery Technologies: Market Forecast 2014-2024
3.7 Ocular Drug Delivery Technologies Market 2014-2024
3.7.1 Ocular Drug Delivery Technologies: Market Forecast 2014-2024
3.8 Nasal Drug Delivery Technologies Market 2014-2024
3.8.1 Nasal Drug Delivery Technologies: Market Forecast 2014-2024

4. Leading National Markets 2014-2024

4.1 The Drug Delivery Technologies Market by Regional Revenue
4.1.1 The Global Distribution of Drug Delivery Technologies in 2013
4.2 Leading National Markets: Forecast, 2014-2024
4.2.1 Changing Market Shares by Region, 2014-2024
4.3 Regional Drug Delivery Technologies Markets: Analysis and Forecasts, 2014-2024
4.3.1 United States: The Largest Market for Drug Delivery Technologies
4.3.2 The EU5 Markets:
4.3.2.1 EU5: Changing Market Shares by Country, 2014-2024
4.3.2.2 Germany: Fiscal Austerity Programs and Spending Cuts
4.3.2.3 France: Strong Drug Discovery Landscape
4.3.2.4 UK: An Increasingly Service-Oriented Market
4.3.2.5 Spain: Recovering Economy to Stimulate Healthcare Investment
4.3.2.6 Italy: Changing Reimbursement Culture Will Aid Market Growth
4.3.3 Japan: Aging Population Stimulating Drug Demand
4.3.4 China: Intensive Talent Resource and Relative Low Cost
4.3.5 India: A Hotbed For Drug Delivery Technology Manufacturing and Outsourcing
4.3.6 Brazil: Government Subsidies Boosting Drug Production
4.3.7 Russia: Availability of Custom Libraries for Drug Molecules Will Catalyse Growth
4.3.8 South Korea: Acquisition of Promising Overseas Companies Will Aid Market Growth
4.3.9 Mexico: Government Initiatives and Regulatory Changes Boosting Market Growth
4.3.10 Rest of the World

5. Leading Drug Classes Offering Growth for Drug Delivery Technologies

5.1 Therapeutic Areas Offering Growth Opportunities
5.2 Biologics: A Future Driver for Growth in Drug Delivery Technologies
5.2.1 Leading Classes of Biological Drugs, 2013
5.3 Monoclonal Antibodies: Largest Sector in Biologics
5.3.1 Monoclonal Antibodies: Prospects, Forecast, and Implications for Drug Delivery Technologies
5.4 Human Insulins
5.4.1 Insulins: Prospects, Forecast, and Implications for Drug Delivery Technologies
5.4.2 Exubera: An Alternative Delivery Method for Biological Drugs
5.4.2.1 The First Inhaled Insulin
5.4.2.2 A History of Exubera: Development and Post-Marketing
5.4.3 Generex and MannKind Developing Next-Generation Oral Insulins
5.4.4 Challenges Facing Oral-lyn and Afrezza
5.5 Interferons
5.5.1 Interferons: Prospects, Forecast, and Implications for Drug Delivery Technologies
5.6 Erythropoietin Products
5.6.1 Erythropoietins: Prospects, Forecast, and Implications for Drug Delivery Technologies
5.7 Granular-Colony Stimulating Factors (G-CSF)
5.7.1 Granular-Colony Stimulating Factors (G-CSF): Prospects, Forecast, and Implications for Drug Delivery Technologies
5.8 Recombinant Coagulation Factors
5.8.1 Recombinant Coagulation Factors: Prospects, Forecast, and Implications for Drug Delivery Technologies
5.9 Other Therapeutic Proteins
5.9.1 Other therapeutic Proteins: Prospects, Forecast, and Implications for Drug Delivery Technologies
5.10 The Biosimilars Market in 2013
5.10.1 Biosimilars: Prospects, Forecast, and Implications for Drug Delivery Technologies
5.11 The Vaccines Market in 2013
5.11.1 Vaccines: Market Forecast 2014-2024
5.12 The Role of Biologics in the Drug Delivery Technologies Market

6. Leading Companies in the Drug Delivery Technologies Market, 2014

6.1 Drug Delivery Technologies: A Fragmented Market
6.2 Leading Companies in Inhaled Drug Delivery Technologies
6.2.1 3M: A Global Health Information Systems Provider
6.2.1.1 3M Healthcare Revenue Analysis, 2013
6.2.1.2 3M’s Drug Delivery Technologies
6.2.1.2.1 Protein and Peptide Delivery
6.2.1.2.2 Excipient Technology for CFC-Free Inhalers
6.2.1.2.3 Actuator Technology for Metered Dose Inhalers
6.2.1.2.4 Particle Engineering Technology
6.2.2 Aradigm Corporation
6.2.2.1 AERx Drug Delivery System
6.2.2.2 Aradigm’s Partnerships
6.2.2.3 Aradigm’s Pipeline Products
6.2.3 Vectura Group
6.2.3.1 Vectura’s Technologies and Products
6.2.3.2 Vectura’s Development Pipeline
6.3 Leading Companies in Oral Drug Delivery Technologies
6.3.1 Applied Pharma Research (APR)
6.3.1.1 APR’s Technology and Product Offerings
6.3.2 Catalent Pharma
6.3.2.1 Catalent’s Drug Delivery Technologies
6.3.2.2 Catalent Revenue Analysis, 2009-2013
6.3.2.3 Catalent’s Recent Activities
6.3.3 Emisphere Technologies
6.3.3.1 Emisphere’s Eligen Technology
6.3.3.2 Emisphere Revenue Analysis, 2010-2013
6.3.3.3 Emisphere: Pipeline Products
6.3.4 Ethypharm
6.3.4.1 Ethypharm’s Drug Delivery Technologies
6.3.4.2 Ethypharm’s Currently Marketed Products
6.3.5 Glycologic
6.3.5.1 Glycologic’s Drug Delivery Technologies
6.3.5.2 Glycologic’s Pipeline Developments
6.4 Leading Companies in Injectable Drug Delivery Technologies
6.4.1 Alkermes
6.4.1.1 Alkerme’s Drug Delivery Technologies
6.4.1.2 Alkermes Revenue Analysis, 2009-2013
6.4.1.3 Alkerme’s Product Pipeline
6.4.2 Pacira Pharmaceuticals
6.4.2.1 Pacira’s Injectable Sustained–Release Technologies
6.4.2.2 Pacira Pharmaceuticals: Revenue Analysis, 2009-2013
6.5 Leading Companies in Transdermal Drug Delivery Technologies
6.5.1 Nanopass Technologies
6.5.1.1 Nanopass Drug Delivery Products
6.5.1.1.1 Anti-aging Microdermabrasion
6.5.1.1.2 Microjet Needle
6.5.2 Noven Pharmaceuticals
6.5.2.1 Noven Pharmaceuticals’ Transdermal Products
6.5.2.2 Noven’s Development Pipeline
6.6 Leading Companies for Transmucosal Drug Delivery
6.6.1 CIMA Labs
6.6.1.1 CIMA’s Transmucosal Drug Delivery Technologies
6.6.1.2 The OTS System
6.6.1.3 OraVescent Technology
6.6.2 Columbia Laboratories
6.6.2.1 Columbia Labs’ Bioadhesive Delivery Technology
6.6.2.2 Columbia Labs’ Products
6.6.2.3 Columbia Labs Revenue Analysis, 2009-2013
6.6.3 Generex Biotechnology Corporation
6.6.3.1 Generex’s Products
6.6.3.2 Generex: Revenue Analysis, 2011-2013
6.7 Leading Implantable Drug Delivery Technology Companies
6.7.1 pSivida Corporation
6.7.1.1 pSivida’s Drug Delivery Technologies
6.7.1.1.1 Durasert Technology
6.7.1.1.2 Tethadur Technology
6.7.2 pSivida Products

7. Qualitative Analysis of the Drug Delivery Technologies Market 2014-2024

7.1 SWOT Analysis of the Drug Delivery Technologies Market, 2014-2024
7.2 Strengths
7.2.1 Biosimilars: Legislations Encouraging Innovation
7.2.2 Patent Expiries and the Resulting Increase in Competition Will Favour Drug Delivery Technologies
7.2.3 Monoclonal Antibodies Will Drive Delivery Technologies
7.2.4 PEGylation Assisting Growth
7.3 Weaknesses
7.3.1 Risk-Conscious Regulatory Bodies Will Make Approval Difficult
7.4 Opportunities
7.4.1 Nanotechnology: Innovations That Will Benefit Drug Delivery
7.4.2 Possible New Delivery Methods for Insulin
7.4.3 Availability of Cost effective Solutions Will Stimulate Uptake of Drug Delivery Technologies
7.5 Threats
7.5.1 The Conservative Mindset of Drug Developers May Hinder Innovation in Drug Delivery
7.5.2 The Current Limit on Feasible Route of Administration for Biotech Drugs May Limit Drug Delivery Growth
7.5.3 Lifecycle Management via Protein Engineering Blurs Drug Delivery Lines

8. Expert Opinions

8.1 Interview with Dr Sven Frokjaer, Dean and Professor of Pharmaceutical Sciences, University of Copenhagen, Denmark
8.1.1 On the Current State of Drug Delivery Technologies
8.1.2 The ‘Magic Bullet’ – A Challenge for Innovation
8.1.3 Self-Assembling Protein Systems and the Use of Nanostructures for Drug Targeting
8.1.4 Technological Developments in Drug Development – Quantum Dots, Silicon Structures, and Polymeric Materials
8.1.5 On Future Challenges and Opportunities
8.2 Interview with Dr Claus Michael Lehr, Head of Department, Drug Delivery at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)
8.2.1 The Need for Novel Delivery Mechanisms Driving Growth
8.2.2 Therapeutic Areas That Are Propelling Drug Delivery Technologies
8.2.3 Drug Delivery Barriers and the Need for Targeting
8.2.4 Advancements in Drug Delivery in the Coming Years
8.2.5 Future Challenges for Drug Delivery Technologies
8.2.6 Future Opportunities for Drug Delivery Technologies

9. Conclusion

9.1 Market Overview
9.2 Commercial Drivers for Drug Delivery Technology
9.3 Transdermal Drug Delivery Technologies Set For High Growth
9.4 Biologics Will Drive Market Growth
9.5 Leading Companies in the Drug Delivery Technologies Market
9.6 Growth Concentrated in Developed Markets and in the Innovative Markets of South America and South Asia
9.7 Future Prospects for Drug Delivery Technologies

List of Tables

Table 2.1 Top 10 Biotech Drugs by Sales ($bn), 2013
Table 2.2 Top 10 Biopharma Companies: Revenues ($m) & R&D Expenditure ($m), 2012
Table 2.3 Amino Acid Changes for Human Insulin Analogues
Table 3.1 Functions of Drug Delivery Technologies
Table 3.2 The Global Drug Delivery Technologies Market: Revenue ($bn) and Market Shares (%) by Sector, 2013
Table 3.3 The Global Drug Delivery Technologies Market: Market Forecast ($bn, AGR%, CAGR%) by Sector, 2013-2024
Table 3.4 Global Drug Delivery Technologies Market Forecast: CAGR (%) by Sector, 2013-2018, 2018-2024, 2013-2024
Table 3.5 The Global Drug Delivery Technologies Market: Revenue ($bn) by Sector, 2013, 2018, 2024
Table 3.6 The Global Drug Delivery Technologies Market: Market Share (%) by Sector, 2013, 2018, 2024
Table 3.7 Oral Drug Delivery Technologies Market: Market Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 3.8 Inhalation Drug Delivery Technologies Market: Market Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 3.9 Injectable/Implants Drug Delivery Technologies Market: Market Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 3.10 Transdermal Drug Delivery Technologies Market: Market Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 3.11 Ocular Drug Delivery Technologies Market: Market Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 3.12 Nasal Drug Delivery Technologies Market: Market Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 4.1 The Global Drug Delivery Technologies Market: Revenue ($bn) and Market Share (%) by Region, 2013
Table 4.2 Drug Delivery Technologies Market: Revenue Forecast ($bn, AGR%, CAGR%) by Region, 2013-2024
Table 4.3 Drug Delivery Technologies Market Forecast: CAGR (%) by Region, 2013-2018, 2018-2024, and 2013-2024
Table 4.4 Drug Delivery Technologies Market Forecast: Market Shares (%) by Region, 2013, 2018, 2024
Table 4.5 US Drug Delivery Technologies Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 4.6 US Drug Delivery Technologies Market: Revenue Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 4.7 The EU5 Drug Delivery Technologies Market Forecast: Market Size ($bn), Market Share (%) and CAGR (%), 2013-2024
Table 4.8 The EU5 Drug Delivery Technologies Market: Revenue ($bn) and Market Share (%) by Country, 2013
Table 4.9 The EU5 Drug Delivery Technologies Market: Revenue Forecast ($bn, AGR%, CAGR%) by Region, 2013-2024
Table 4.10 EU5 Drug Delivery Technologies Market: Market Share (%) by Country, 2013, 2018, 2024
Table 4.11 The German Drug Delivery Technologies Market Forecast: Revenue ($bn), Market Rank, Market Share (%) and CAGR (%), 2013-2024
Table 4.12 The German Drug Delivery Technologies Market: Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 4.13 The French Drug Delivery Technologies Market Forecast: Revenue ($bn), Market Rank, Market Share (%) and CAGR (%), 2013-2024
Table 4.14 The French Drug Delivery Technologies Market: Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 4.15 The UK Drug Delivery Technologies Market Forecast: Revenue ($bn), Market Rank, Market Share (%) and CAGR (%), 2013-2024
Table 4.16 The UK Drug Delivery Technologies Market: Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 4.17 The Spanish Drug Delivery Technologies Market Forecast: Revenue ($bn), Market Rank, Market Share (%) and CAGR (%), 2013-2024
Table 4.18 The Spanish Drug Delivery Technologies Market: Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 4.19 The Italian Drug Delivery Technologies Market Forecast: Revenue ($bn), Market Rank, Market Share (%) and CAGR (%), 2013-2024
Table 4.20 The Italian Drug Delivery Technologies Market: Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 4.21 The Japanese Drug Delivery Technologies Market Forecast: Revenue ($bn), Market Rank, Market Share (%) and CAGR (%), 2013-2024
Table 4.22 The Japanese Drug Delivery Technologies Market: Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 4.23 The Chinese Drug Delivery Technologies Market Forecast: Revenue ($bn), Market Rank, Market Share (%) and CAGR (%), 2013-2024
Table 4.24 The Chinese Drug Delivery Technologies Market: Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 4.25 The Indian Drug Delivery Technologies Market Forecast: Revenue ($bn), Market Rank, Market Share (%) and CAGR (%), 2013-2024
Table 4.26 The Indian Drug Delivery Technologies Market: Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 4.27 The Brazilian Drug Delivery Technologies Market Forecast: Revenue ($bn), Market Rank, Market Share (%) and CAGR (%), 2013-2024
Table 4.28 The Brazilian Drug Delivery Technologies Market: Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 4.29 The Russian Drug Delivery Technologies Market Forecast: Revenue ($bn), Market Rank, Market Share (%) and CAGR (%), 2013-2024
Table 4.30 The Russian Drug Delivery Technologies Market: Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 4.31 The South Korean Drug Delivery Technologies Market Forecast: Revenue ($bn), Market Rank, Market Share (%) and CAGR (%), 2013-2024
Table 4.32 The South Korean Drug Delivery Technologies Market: Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 4.33 The Mexican Drug Delivery Technologies Market Forecast: Revenue ($bn), Market Rank, Market Share (%) and CAGR (%), 2013-2024
Table 4.34 The Mexican Drug Delivery Technologies Market: Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 4.35 The Rest of the World’s Drug Delivery Technologies Market Forecast: Revenue ($bn), Market Share (%) and CAGR (%), 2013-2024
Table 4.36 The Rest of the World’s Drug Delivery Technologies Markets: Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 5.1 Leading Biopharmaceutical Drugs Driving the Drug Delivery Technologies Market: Total Sales ($bn), 2013
Table 5.2 Some Leading Monoclonal Antibody Drugs, 2013
Table 5.3 Monoclonal Antibodies: Global Sales Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 5.4 Insulins: Global Sales Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 5.5 Selected Interferon Products: Generic Name, Brand Name, Manufacturer, 2014
Table 5.6 Interferons: Global Sales Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 5.7 Erythropoietins: Global Sales Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 5.8 Granular-Colony Stimulating Factors (G-CSF): Global Sales Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 5.9 Recombinant Coagulation Factors: Selected Products, 2014
Table 5.10 Recombinant Coagulation Factors: Global Sales Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 5.11 Human Growth Hormones: Selected Products, 2014
Table 5.12 Immunosuppressants: Selected Products, 2014
Table 5.13 Other Therapeutic Proteins: Global Sales Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 5.14 Biosimilars: Selected Products, 2014
Table 5.15 Biosimilars: Global Sales Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 5.16 Biosimilars: Selected Products, 2014
Table 5.17 Vaccines: Global Sales Forecast ($bn, AGR%, CAGR%), 2013-2024
Table 6.1 3M: Net Sales ($bn) by Franchise, 2013
Table 6.2 3M: Historical Healthcare Revenue ($bn, AGR %), 2008-2013
Table 6.3 Aradigm: Pipeline Products, 2014
Table 6.4 Vectura Group: Current Products and Description, 2014
Table 6.5 Vectura Group: Products Under Development, 2014
Table 6.6 Catalent Pharma: Historical Revenue ($m, AGR %), 2009-2013
Table 6.7 Emisphere Technologies: Historical Financial Information ($m) 2010-2012
Table 6.8 Ethypharm’s Pain Relieving Products, 2014
Table 6.9 Alkermes: Historical Revenue ($m, AGR %), 2009-2013
Table 6.10 Alkerme’s Product Pipeline, 2014
Table 6.11 Pacira Pharmaceuticals: Products and Therapeutic Indication, 2014
Table 6.12 Pacira Pharmaceuticals: Historical Revenue ($m, AGR %), 2009-2013
Table 6.13 Noven Pharmaceuticals: Products, Drug Delivery Systems, and Drug Marketers, 2014
Table 6.14 Noven Pharmaceuticals: Marketed and Pipeline Transdermal Products, 2014
Table 6.15 Columbia Laboratories: Historical Revenue ($m, AGR %), 2008-2013
Table 7.1 Drug Delivery Technologies: Market Drivers and Restraints 2014-2024
Table 7.2 SWOT Analysis of the drug delivery Technologies Market, 2014-2024
Table 7.3 Selected Leading Drugs Expected to Lose Patent Protection 2013-2015
Table 7.4 Monoclonal Antibody Therapies Approved by the FDA, 2004-2011
Table 9.1 Global Drug Delivery Technologies: Market Forecast ($bn, CAGR%), 2013, 2018, 2021, 2024
Table 9.2 Global Drug Delivery Technologies: Market Forecast ($bn) by Sector, 2013, 2018, 2021, 2024
Table 9.3 Global Drug Delivery Technologies: Market Share (%) by Region, 2013, 2018, 2021, 2024

List of Figures

Figure 1.1 The Global Over 65 Population: Forecast (millions, AGR%), 2013-2024
Figure 1.2 Global Drug Delivery Technologies Market Segmentation Overview
Figure 1.3 Biologic Drugs: Overview of Forecasted Drug Classes
Figure 2.1 Possible Mode of Administration for Biological Drugs
Figure 3.1 The Global Drug Delivery Technologies Market: Revenue ($bn) by Sector, 2013
Figure 3.2 The Global Drug Delivery Technologies Market: Market Forecast ($bn, AGR%), 2013-2024
Figure 3.3 Global Drug Delivery Technologies Market Forecast: CAGR (%) by Sector, 2013-2018
Figure 3.4 Global Drug Delivery Technologies Market Forecast: CAGR (%) by Sector, 2018-2024
Figure 3.5 Global Drug Delivery Technologies Market Forecast: CAGR (%) by Sector, 2013-2024
Figure 3.6 The Global Drug Delivery Technologies Market: Revenue ($bn) by Sector, 2013, 2018, 2024
Figure 3.7 The Global Drug Delivery Technologies Market: Market Share (%) by Sector, 2013
Figure 3.8 The Global Drug Delivery Technologies Market: Market Share (%) by Sector, 2018
Figure 3.9 The Global Drug Delivery Technologies Market: Market Share (%) by Sector, 2024
Figure 3.10 Oral Drug Delivery Technologies Market: Market Forecast ($bn, AGR%), 2013-2024
Figure 3.11 Inhalation Drug Delivery Technologies Market: Market Forecast ($bn, AGR%), 2013-2024
Figure 3.12 Injectable/Implants Drug Delivery Technologies Market: Market Forecast ($bn, AGR%), 2013-2024
Figure 3.13 Transdermal Drug Delivery Technologies Market: Market Forecast ($bn, AGR%), 2013-2024
Figure 3.14 Ocular Drug Delivery Technologies Market: Market Forecast ($bn, AGR%), 2013-2024
Figure 3.15 Nasal Drug Delivery Technologies Market: Market Forecast ($bn, AGR%), 2013-2024
Figure 4.1 The Global Drug Delivery Technologies Market: Revenue ($bn) by Region, 2013
Figure 4.2 US, EU5, Japan, China and South India Drug Delivery Technologies Market: Revenue Forecast ($bn), 2013-2024
Figure 4.3 Brazil, Russia, South Korea, and Mexico Drug Delivery Technologies Market: Revenue Forecast ($bn), 2013-2024
Figure 4.4 Drug Delivery Technologies Market Forecast: CAGR (%) by Region, 2013-2018
Figure 4.5 Drug Delivery Technologies Market Forecast: CAGR (%) by Region, 2018-2024
Figure 4.6 Drug Delivery Technologies Market Forecast: CAGR (%) by Region, 2013-2024
Figure 4.7 Drug Delivery Technologies Market Forecast: Market Shares (%) by Region, 2013
Figure 4.8 Drug Delivery Technologies Market Forecast: Market Shares (%) by Region, 2018
Figure 4.9 Drug Delivery Technologies Market Forecast: Market Shares (%) by Region, 2024
Figure 4.10 US Drug Delivery Technologies Market: Revenue Forecast ($bn, AGR%), 2013-2024
Figure 4.11 The EU5 Drug Delivery Technologies Market: Market Size ($bn) by Region, 2013
Figure 4.12 Germany, UK, France, Spain, and Italy Drug Delivery Technologies Market: Revenue Forecast ($bn), 2013-2024
Figure 4.13 The EU5 Drug Delivery Technologies Market: Market Shares (%) by Country, 2013
Figure 4.14 The EU5 Drug Delivery Technologies Market: Market Shares (%) by Country, 2018
Figure 4.15 The EU5 Drug Delivery Technologies Market: Market Shares (%) by Country, 2024
Figure 4.16 The German Drug Delivery Technologies Market: Revenue Forecast ($bn, AGR%), 2013-2024
Figure 4.17 The French Drug Delivery Technologies Market: Revenue Forecast ($bn, AGR%), 2013-2024
Figure 4.18 The UK Drug Delivery Technologies Market: Revenue Forecast ($bn, AGR%), 2013-2024
Figure 4.19 The Spanish Drug Delivery Technologies Market: Revenue Forecast ($bn, AGR%), 2013-2024
Figure 4.20 The Italian Drug Delivery Technologies Market: Revenue Forecast ($bn, AGR%), 2013-2024
Figure 4.21 The Japanese Drug Delivery Technologies Market: Revenue Forecast ($bn, AGR%), 2013-2024
Figure 4.22 Japanese Over-65 Population and Forecast (%): 2010, 2013, 2035, 2060
Figure 4.23 The Chinese Drug Delivery Technologies Market: Revenue Forecast ($bn, AGR%), 2013-2024
Figure 4.24 The Indian Drug Delivery Technologies Market: Revenue Forecast ($bn, AGR%), 2013-2024
Figure 4.25 The Brazilian Drug Delivery Technologies Market: Revenue Forecast ($bn, AGR%), 2013-2024
Figure 4.26 The Russian Drug Delivery Technologies Market: Revenue Forecast ($bn, AGR%), 2013-2024
Figure 4.27 The South Korean Drug Delivery Technologies Market: Revenue Forecast ($bn, AGR%), 2013-2024
Figure 4.28 The Mexican Drug Delivery Technologies Market: Revenue Forecast ($bn, AGR%), 2013-2024
Figure 4.29 The Rest of the World’s Drug Delivery Technologies Markets: Revenue Forecast ($bn, AGR%), 2013-2024
Figure 5.1 Monoclonal Antibodies: Global Sales Forecast ($bn, AGR%), 2013-2024
Figure 5.2 Insulins: Global Sales Forecast ($bn, AGR%), 2013-2024
Figure 5.3 Interferons: Global Sales Forecast ($bn, AGR%), 2013-2024
Figure 5.4 Erythropoietins: Global Sales Forecast ($bn, AGR%), 2013-2024
Figure 5.5 Granular-Colony Stimulating Factors (G-CSF): Global Sales Forecast ($bn, AGR%), 2013-2024
Figure 5.6 Recombinant Coagulation Factors: Global Sales Forecast ($bn, AGR%), 2013-2024
Figure 5.7 Other Therapeutic Proteins: Global Sales Forecast ($bn, AGR%), 2013-2024
Figure 5.8 Biosimilars: Global Sales Forecast ($bn, AGR%), 2013-2024
Figure 5.9 Vaccines: Global Sales Forecast ($bn, AGR%), 2013-2024
Figure 6.1 3M: Revenue Shares (%) by Franchise, 2013
Figure 6.2 3M: Historical Healthcare Revenue ($bn), 2008-2013
Figure 6.3 Catalent Pharma: Historical Revenue ($m, AGR%), 2009-2013
Figure 6.4 Emisphere Technologies: Historical Financial Information ($m) 2010-2012
Figure 6.5 Alkermes: Historical Revenue ($m), 2009-2013
Figure 6.6 Pacira Pharmaceuticals: Historical Revenue ($m), 2009-2013
Figure 6.7 Columbia Laboratories: Historical Revenue ($m), 2008-2013
Figure 7.1 Approaches to Drug Delivery in Biologics, 2014
Figure 9.1 Global Drug Delivery Technologies: Market Forecast ($bn), 2013, 2018, 2021, 2024
Figure 9.2 Global Drug Delivery Technologies: Market Forecast ($bn) by Sector, 2013-2024

掲載企業リスト

Companies Listed

3M
Abbott
Adamas Pharmaceuticals
Alexion
Alimera Sciences
Alkermes
Allergan
Alpha MOS
Amgen
Amylin Pharmaceuticals (Bristol-Myers Squibb)
Antares Pharma
Antigen Express Inc (Generex)
Applied Pharma Research
Aptuit
Aradigm Corporation
Astellas
Bausch & Lomb
Baxter International
Bayer Healthcare Pharmaceuticals
Berna Biotech
Biocad
Biocon
Biogen Idec
Bioject Medical Technologies
Biopartners
Biotechpharma
Boehringer Ingelheim
Cardinal Health
Catalent Pharma Solutions
Chiron Corporation
CIMA Labs (Cephalon)
Circassia
Columbia Laboratories
Conba Pharmaceutical
CSL Behring
CT Arzneimittel GmbH
Daiichi
Dendreon
Dong-A Socio Holdings
Dr Reddy’s Laboratories
Elan Corporation (Perrigo)
Eli Lilly
Elite Pharmaceuticals
Emisphere Technologies
Ethypharm
Eurofarma
Evotec
Ferring Pharmaceuticals
Flynn Pharma
Fresenius SE & Co
Genentech (Roche)
Generex Biotechnology Corporation
GeneScience Pharmaceuticals
Genmab
Genzyme (Sanofi)
Gilead Sciences
GlaxoSmithKline
Glycologic
Hospira
Human Genome Sciences
Janssen Biotech
Johnson & Johnson
Labtec
LG Life Sciences
MannKind
Medimetrics
Merck Serono
Millennium Pharma (Takeda)
Mitsubishi Tanabe Pharma
Molecular Profiles
MonoSol Rx
Mundi Pharma
Nanopass Technologies
Nektar Therapeutics
Nordic Bioscience
Novartis
Noven Pharmaceuticals (Hisamitsu Pharmaceuticals)
Novo Nordisk
Novogyne Pharmaceuticals
Pacira Pharmaceuticals
Par Pharmaceutical
Pfizer
pSivida Corporation
Ranbaxy
Regeneron
Roche Group
Sandoz
Sanofi-Aventis
Schering-Plough (Merck & Co)
Seattle Genetics
SHL Group
Sigma-Tau Pharmasource
SkyePharma PLC
Strativa Pharmaceuticals
Takeda
Talecris Biotherapeutics
Teva
The Blackstone Group
UCB
Upsher-Smith Laboratories
Vectura Group
Vestiq Pharmaceuticals
Wyeth Pharmaceuticals (Pfizer)

Organisations Mentioned in the Report

Agenzia Italiana del Farmaco (AIFA)
Center for Disease Control [US]
Federal Commission for the Protection against Sanitary Risks (COFEPRIS)
Johns Hopkins University [US]
Kresge Eye Institute (Wayne State University, Detroit, US)
National Institute for Health and Clinical Excellence (NICE)
National Institute for Population and Social Security Research (IPSS) [Japan]
Russian Corporation of Nanotechnologies (Rusnano)
The Research Foundation for Microbial Diseases of Osaka University [Japan]
University of Copenhagen
US Food and Drug Administration (FDA)
US Securities and Exchange Commission (SEC)

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

2319881.jpg国内外のスマートグリッド関連ニュース、リサーチ情報等を収集し隔週でお届けいたします。日本そして海外の企業動向、新製品、政府支援、技術開発、規格、導入事例、投資、調査発表など幅広く情報を定期配信いたします。
スマートグリッド・ニュースへLinkIcon


ニュースページへLinkIcon

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。